Press "Enter" to skip to content

FDA gives go ahead for 3rd Vaccine Dose

According to two persons familiar with the plans, the Food and Drug Administration (FDA) is expected to change the emergency use authorizations for the Pfizer and Moderna Covid-19 vaccines on Thursday to allow people with impaired immune systems to receive a third dose. The decision would come after a panel of CDC experts convened in July and recommended that higher doses for immunocompromised individuals be implemented.

Doctors believe it’s becoming increasingly obvious that many of these people are still vulnerable to Covid after vaccination because their immune systems may not be able to generate a strong enough reaction to the doses. According to the CDC, around 2.7 percent of adults in the United States are immunocompromised. It’s unclear which groups will be affected by the FDA‘s impending action. Organ transplant recipients, cancer patients, and HIV patients are just a few examples of immunocompromised patients.

Patients who have organ transplants, for example, must take drugs to suppress their immune systems so that the new organs are not rejected by their bodies. After vaccination, the majority of these patients never produced antibodies to the coronavirus, according to one small study. The others merely created rudimentary defences.A third dose raised their antibody levels in that Johns Hopkins University study. Doctors have continued to advise such patients to continue with physical separation and mask use despite the vaccines, so a rise in immunity would certainly be welcomed by individuals who never had a satisfactory response from the first two shots.

The Pfizer and Moderna vaccines have both been found to be highly effective at preventing hospitalisation and mortality in fully immunised, otherwise healthy adults. The CDC advisory panel will meet on Friday to consider whether or not to suggest a third injection for immunocompromised persons. Before doctors can start prescribing larger doses, the panel must give its approval.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *